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Background
Approximately 10 percent of women with invasive
epithelial ovarian cancer (EOC) carry deleterious germ-
line mutations in BRCA1 or BRCA2. However, the
impact of these mutations on ovarian cancer prognosis
remains unclear.
Methods
We performed an international multi-center study of
1,470 EOC cases with pathogenic germline mutations in
BRCA1 (1,134) or BRCA2 (336) and 2,814 non-carriers.
Our goal was to further characterize the survival of
BRCA carriers with EOC compared to non-carriers and
to determine whether BRCA1 and BRCA2 carriers show
similar survival patterns. Cox proportional hazards
regression, both unadjusted and adjusted for other prog-
nostic variables, was used to measure differences in
overall survival during the five years following diagnosis.
Results
The five-year overall survival was 36 percent for non-
carriers, 44 percent for BRCA1 carriers and 52 percent
for BRCA2 carriers. After adjusting for study and year of
diagnosis, BRCA1 and BRCA2 carriers showed a more
favorable survival than non-carriers (BRCA1, HR=0.78;
95% CI=0.68-0.89, P=2x10
-4; BRCA2, HR = 0.61; 95%
CI=0.50-0.76, P=6x10
-6;). These survival differences
remained after adjustment for stage, grade, histology
and age at diagnosis (BRCA1, HR=0.73, 95% CI=0.64-
0.84, P=2x10
-5; BRCA2, HR = 0.49, 95% CI=0.39-0.61,
P=3x10
-10).
Conclusions
We observed a significantly improved survival in germ-
line BRCA1 and BRCA2 mutation carriers with EOC
compared to non-carriers. BRCA2 carriers had the most
favorable outcome with a distinct clinical course from
BRCA1 carriers. The magnitude of the differences we
observed highlight the need for clinical trials in EOC to
be stratified by BRCA1/2 status and suggest that the
routine testing of women presenting with high-grade
serous EOC may be warranted.
Author details
1Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda MD 20892, USA.
2Queensland Institute of Medical Research, Locked
Bag 2000, Royal Brisbane Hospital, Herston, QLD 4029, Australia.
3Addenbrooke’s Hospital, Hills Road, Cambridge CB2 OQQ, UK.
4Cancer and
Radiation Epidemiology Unit, Gertner Institute for Epidemiology and Health
Policy, Sheba Medical Center, Tel Hashomer, 52621, Israel.
5Sackler Faculty of
Medicine, Tel-Aviv University, Tel-Aviv, Israel.
6Gynaecological Cancer
Research Laboratories, UCL EGA Institute for Women’s Health, University
College London, London, UK.
7Department of Preventive Medicine, Keck
School of Medicine University of Southern California, Los Angeles, California,
90033, USA.
8Centre for Cancer Genetic Epidemiology, Department of Public
Health and Primary Care, University of Cambridge, Strangeways Research
Laboratory, Worts Causeway, Cambridge CB1 8RN, UK.
9Cancer Research
United Kingdom Department of Oncology and Department of Public Health
and Primary Care, University of Cambridge, Strangeways Research
Laboratory, Worts Causeway, Cambridge CB1 8RN, UK.
Published: 12 April 2012
1Division of Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda MD 20892, USA
Full list of author information is available at the end of the article
Bolton et al. Hereditary Cancer in Clinical Practice 2012, 10(Suppl 2):A27
http://www.hccpjournal.com/content/10/S2/A27
© 2012 Bolton et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.doi:10.1186/1897-4287-10-S2-A27
Cite this article as: Bolton et al.: A multi-center study to evaluate the
impact of germline BRCA1 and BRCA2 mutations on ovarian cancer
survival. Hereditary Cancer in Clinical Practice 2012 10(Suppl 2):A27.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bolton et al. Hereditary Cancer in Clinical Practice 2012, 10(Suppl 2):A27
http://www.hccpjournal.com/content/10/S2/A27
Page 2 of 2